A $976 million private credit facility is being provided by Goldman Sachs Asset Management, Blackstone, and Apollo to finance BGH Capital’s acquisition of Aspen Pharmacare Holdings' Asia Pacific business. This deal, valued at A$2.37 billion, demonstrates the growing influence of private credit in funding major buyouts, particularly in Australia where traditional bank lending is constrained. The financing is covenant-lite with a margin of approximately 475 basis points.

This financing arrangement highlights the increasing reliance of private equity firms on private credit. The deal's structure, with leverage around 6.5x earnings, is common in today's market. However, Australia’s regulatory bodies are increasing scrutiny of the private credit sector, focusing on valuations, fee transparency, and potential conflicts of interest, which could impact future deals.

BGH Capital, managing A$6.8 billion across eleven portfolio companies, sees this acquisition as one of its largest to date. Private credit has become a crucial funding source as banks tighten lending standards. This trend is expected to continue, particularly as interest rates remain elevated, making private credit an attractive option for both borrowers and lenders.

This deal's success hinges on Aspen Pharmacare's performance in the Asia Pacific region. Investors will closely watch the returns on this investment, as it will likely set the stage for other large healthcare acquisitions. Given the current economic climate, the terms of the private credit facility are quite favorable for the borrowers.